Daiichi Sankyo, Inc. (DSI)
|
|
- Homer Jackson
- 6 years ago
- Views:
Transcription
1 Daiichi Sankyo, Inc. (DSI) Outlook for U.S. Business for 2009 Nov. 7 th, 2007 Joseph P. Pieroni President and CEO Daiichi Sankyo, Inc.
2 Largest Pharmaceutical markets $300 $274.4 Annual Sales (US$ billions) Others 12% Japan 9% $250 $200 U.S. 47% $150 EU 32% $100 $56.7 $50 $31.9 $34.0 $20.5 $20.5 $16.3 $15.5 $0 U.S. Japan Germany France UK Italy Spain Canada page 1 Source: IMS
3 Daiichi Sankyo, Inc. - U.S. Organization Commercial Operations (Parsippany, NJ) (Home Office: 340) Sales Force (1,350) Clinical & Regulatory (Edison, NJ) (260) (# employees) page 2
4 Daiichi Sankyo, Inc. Product Portfolio Product Therapeutic Category Anti-Hypertension Net Sales FY 2007 ($ ($ million) $756 Dyslipidemia $205 Anti-hypertensive $28 Dry Mouth Syndrome $32 Total Total $1,021 $1,021 page 3 Source: Daiichi Sankyo
5 page 4
6 ARB Market Benicar new prescription share continues to grow in ARB Market 45% Mono & Combo New Rx Share 40% DIOVAN / DIOVAN HCT 40.07% 35% 30% COZAAR / HYZAAR 25% 20% 15% 10% AVAPRO / AVALIDE BENICAR / BENICAR HCT ATACAND / ATACAND HCT BENICAR HCT Launch 20.41% 16.64% 5% MICARDIS / MICARDIS HCT 0% TEVETEN / TEVETEN HCT 10/12/07 5/3/02 6/28/02 8/23/02 10/18/02 12/13/02 2/7/03 4/4/03 5/30/03 7/25/03 9/19/03 11/14/03 1/9/04 3/5/04 4/30/04 6/25/04 8/20/04 10/15/04 12/10/04 2/4/05 4/1/05 5/27/05 7/22/05 9/16/05 11/11/05 1/6/06 3/3/06 4/28/06 6/23/06 8/18/06 10/13/06 12/8/06 2/2/07 3/30/07 5/25/07 7/20/07 9/14/07 page 5 Source: IMS National Prescription Audit ( Weekly Data) Mono & Combo NRx Market Share
7 Product Pipeline Products in late stage development Development Stage Product Therapeutic Class Key Characteristics NDA Approved Azor Hypertension highly effective olmesartan combined with amlodipine NDA WelChol* prasugrel** Diabetes Acute Coronary Syndrome only product to reduce both cholesterol and glucose head to head trial versus Plavix *FDA approval expected in November 2007 **FDA filing by year-end page 6
8 New Product Launches FY2007 Q1 Q1 Q2 Q2 Q3 Q3 Q4 Q4 Azor Azor Amlodipine Amlodipine - - olmesartan olmesartan FY2008 Q1 Q1 Q2 Q2 Q3 Q3 Q4 Q4 FY2009 Q1 Q1 Q2 Q2 Q3 Q3 Q4 Q4 WelChol WelChol diabetes diabetes Forest Forest Benicar Benicar co-promotion co-promotion ends ends prasugrel prasugrel Sales Force Expansion ,350 1,550 2,200 page 7
9
10 The AZOR Opportunity amlodipine Market before patent expiration 43 million prescriptions $2.7 billion amlodipine Most successful anti-hypertensive 17 million prescriptions $1.6 billion amlodipine-benazepril Only successful fixed-dose combination page 9 IMS.Health December 2006
11 Amlodipine + ARB Combination Market amlodipine / valsartan (Novartis) -Number 1 ARB combined with amlodipine - Launched June 2007 amlodipine / olmesartan (Daiichi Sankyo) -Fastest growing ARB combined with amolipine -Launched October 2007 page 10
12 AZOR vs. amlodipine Mean Change in BP at Week 8 0 amlodipine 5 mg BENICAR olmesartan 40 mg AZOR amlodipine 5mg / olmesartan 40 mg mm Hg Systolic BP -16 An additional 67% reduction Diastolic BP page 11 Data on File. Daiichi Sankyo, Inc. AZOR package insert
13 AZOR vs. amlodipine Mean Change in BP at Week 8 0 amlodipine 10 mg BENICAR olmesartan 40 mg AZOR amlodipine 10 mg / olmesartan 40 mg -5 mm Hg Systolic BP An additional 53% reduction -30 Diastolic BP page 12 Data on File. Daiichi Sankyo, Inc. AZOR package insert
14 AZOR vs. amlodipine Placebo-subtracted Incidence of Edema Percentage of Patients % 54% reduction in Edema 13.9% 11.2% 0.0 amlodipine 10mg Azor 10/20mg Azor 10/40mg page 13 Data on File. Daiichi Sankyo, Inc. AZOR package insert
15 Anti-hypertensive Market ARBs, Norvasc and Lotrel ARBs and Lotrel -account for 71% of market - fastest growing classes 2006 Anti-hypertensive $ sales Sales Growth (2005 vs. 2006) BBs 14% Diuretics 3% ACEIs 12% Norvasc CCBs 27% 71% Lotrel 10% ARBs 34% % % Diuretics CCBs BBs* ARBs* Lotrel -16.5% ACEIs* 1.7% 14.7% 14.3% Total Sales = $18.4 B page 14 IMS.Health December 2006
16 Anti-hypertensive Market Polytherapy Growing in hypertension therapy % of Patients on Polytherapy 100% 80% 60% 40% 20% 0% 48% 45% 52% Stage 1 Stage Physicians using more combination therapy as a first line agent and are quicker to switch to combination therapy for patients not at goal 74% 75% 82% page 15 IMS,.Health NPA data
17 Azor vs. Benicar Patient Targets Stage 1 Stage 1 Stage 2 Predominantly Stage 2 -More Severe -Difficult to treat Typically Complicated amlodipine & Lotrel Patients page 16
18 Benicar, Azor Targets Benicar, Benicar HCT AZOR ARB ARB/HCT Amlo Lotrel Exforge page 17
19 Product Positioning For patients that need greater blood pressure control Azor is the that because so that combination of the most-prescribed CCB, amlodipine, and the most potent ARB, olmesartan provides superior blood pressure reduction (up to 40 mm Hg) across many patient types it targets two distinct pathways of hypertension through calcium channel blockade and angiotensin II blockade patients feel reassured that they can get BP control with the convenience of a single pill. page 18
20 page 19
21 Cholesterol New Cholesterol + Diabetes page 20
22 Markets for Cholesterol and Diabetes are growing HC Prescription Trends Diabetes Prescription Trends TRx Vol (M) TRx Vol (M) MAT 2003 MAT 2004 MAT 2005 MAT 2006 MAT MAT 2003 MAT 2004 MAT 2005 MAT 2006 MAT 2007 page 21 IMS Health, National Prescription Audit, 2007
23 Aggressive Goals for both Cholesterol and Diabetes Cholesterol 2007 NCEP Guidelines LDL-C goal In high-risk patients (<100 mg/dl) Diabetes 2007 ADA Guidelines Patients in general (<7% A1C) Current therapeutic option for patients with CHD (<70 mg/dl): Especially patients with diabetes Current goal for individual patients (<6% A1C): As close to normal as possible page 22
24 Patients Are not at Goal Percent of people not at Goal in U.S. Cholesterol >50% Diabetes 67% page 23
25 Cholesterol Treatment Increase in Combination therapy page 24
26 Diabetes Treatment Increase in Combination Therapy page 25
27 Welchol Studies for Glucose lowering Real-World Study Design Metformin Insulin Sulfonylureas + Welchol Metformin Insulin Sulfonylureas + Any Other AD Medications + Welchol page 26
28 Welchol produced Consistent Reductions in A1C Metformin Based* Sulfonylurea Based** Insulin Based A1C Reduction (%) *Bays H et al. Abstracts of the 16th Annual AACE Meeting & Clinical Congress; April 11-15, 2007; Seattle, WA. Abstract 204:18. **Fonseca VA et al. Abstracts of the 16th Annual AACE Meeting & Clinical Congress; April 11-15, 2007; Seattle, WA. Abstract 409:10. Goldberg RB and Truitt K. Presented at: AHA Scientific Sessions 2006; November 12-15, 2006; Chicago, IL. Poster page 27
29 Efficacy Expectations in Diabetes Therapy Results of glucose lowering from recently published trials in similar patient populations 0 Januvia TM Byetta Avandia Welchol A1C Reduction (%) * ** -0.8 Januvia (sitagliptin) Package Insert, April 2007 Byetta (exenatide) Package Insert, September 2007 *Home, PD et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med Jun;24(6): **Pooled analysis (WEL-301, WEL-302, WEL-303), Data on file, Daiichi Sankyo, Inc. page 28
30 Adverse Events Concerns with Diabetic Therapy Not Associated With Welchol Typical Adverse Events Welchol Increased Hypoglycemia Weight Gain Contraindications (CHF, Kidney) Edema CYP450 Interactions NO NO NO NO NO page 29
31 A1C + LDL-C Two Goals One Therapy page 30
32 Product Opportunities Achieve Benicar sales of of $1 $1 billion With patent expiration of Norvasc, Benicar and Diovan will be the major antihypertensive drugs in U.S. Capture significant share share of of ARB-amlo combo market with with Azor Azor amlo olmesartan and amlo valsartan (Exforge-Novartis) will create a new market for ARB-amlodipine combos Significantly increase Welchol sales sales with with new new diabetes indication Novel approach to the treatment of diabetes plus lipid lowering Make prasugrel a blockbuster Success with prasugrel will make DSI a Top-Tier CV Company in U.S. page 31
33 Daiichi Sankyo, Inc. Mid-Term Sales Net Sales ($ Millions) $1,500 $1,000 $500 New Products Current Products $ page 32
34 U.S. Cardiovascular Market Total Total Cardiovascular Cardiovascular Market Market (2006) (2006) $50 $50 Billion Billion Hypertension Hypertension $18.5 $18.5 Hyperlipidemia Hyperlipidemia $21.6 $21.6 Anti-Platelet Anti-Platelet $4.1 $4.1 Anti-Coagulant Anti-Coagulant $3.1 $3.1 Lotrel: Lotrel: $1.5 $1.5 Lipitor: Lipitor: $8.6 $8.6 Plavix: Plavix: $2.9 $2.9 Lovenox: Lovenox: $2.1 $2.1 Toprol Toprol XL: XL: $1.7 $1.7 Diovan: Diovan: $2.3 $2.3 Cozaar: Cozaar: $1.4 $1.4 Crestor: Crestor: $1.3 $1.3 Vytorin: Vytorin: $1.9 $1.9 Zetia: Zetia: $1.5 $1.5 prasugrel prasugrel DU DU 176b 176b Benicar: Benicar: $831 $831 MM MM Welchol: Welchol: $200 $200 MM MM page 33 Source: NCI Analysis; IMS NPA Sales 2006
35 Long-term Strategic Objectives Become Leader Leader in in Hypertension Achieve sales sales of of $2 $2 billion billion with with Benicar franchise and and Azor Azor Become Top Top Tier Tier Cardiovascular Company Hypertension --Benicar, Azor Azor Antiplatelet market market --prasugrel Anti-coagulant market market --DU DU 176b 176b Produce Significant Profit Profit growth for for Daiichi Daiichi Sankyo Achieve significant local local operating profit profit from from onward page 34
36 Contact address regarding this material DAIICHI SANKYO CO., LTD. Corporate Communications Department TEL: FAX: Each numerical value regarding the future prospect in this material is derived from our judgment and assumptions based on the currently available information and may include risk and uncertainty. For this reason, the actual performance data, etc. may differ from the prospective value. page 38
Pharmacy Costs: Can I Make a Difference?
Pharmacy Costs: Can I Make a Difference? Pharmaceutical Market Dynamics What is driving Rx cost up? No New Blockbusters Patent Expirations OTC Market Dynamics Availability Pharmaceutical Companies Unfortunately,
More informationAmlodipine/olmesartan (Azor ) is indicated for the treatment of hypertension, alone or in combination with other antihypertensive medications.
Page 1 of 8 Policies Repository Policy Title Policy Number Oral Antihypertensive Agents FS.CLIN.9 Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product
More informationHTN: 80 mg once daily 23,f 80 mg once daily 23,f Hypertension 40, 80 mg $82.66 (80 mg once daily) HTN: 8-32 mg daily in one or two divided doses 1
Detail-Document #260301 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2010 ~ Volume 26 ~ Number 260301 Comparison of Angiotensin Receptor
More informationAnnual Review of Antihypertensives - Fiscal Year 2009
Annual Review of Antihypertensives - Fiscal Year 2009 Oklahoma HealthCare Authority April 2010 Current Prior Authorization Criteria There are 7 categories of antihypertensive medications currently included
More informationClinical Policy: Angiotesin II Receptor Blockers and Renin Inhibitors Reference Number: CP.HNMC.15 Effective Date: Last Review Date: 08.
Clinical Policy: Reference Number: CP.HNMC.15 Effective Date: 11.16.16 Last Review Date: 08.17 Revision Log Line of Business: Medicaid Medi-Cal See Important Reminder at the end of this policy for important
More informationAngiotensin II Receptor Antagonists (ARBs), Renin Inhibitors, and Combinations Step Therapy Program Summary
OBJECTIVE The intent of the Angiotensin II Receptor Antagonists (ARBs), Renin Inhibitors, and Combinations Step Therapy (ST) program is to encourage use of cost-effective generic products - ACEIs, ACEI
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Antihypertensive Medications Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Antihypertensive Medications Prime Therapeutics will review Prior Authorization
More informationSOLVAY GROUP London Morning Meeting. June 26, 2009
SOLVAY GROUP London Morning Meeting June 2, 9 1 Our fenofibrate franchise Klaus Kirchgassler, MD Sr VP Solvay Pharmaceuticals 2 Summary of lipid lowering market performance in Value Growth vs. previous
More informationAmylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes
Amylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes Daniel M. Bradbury President & Chief Executive Officer JPMorgan Healthcare Conference January 12, 2009 Safe Harbor Statement
More informationApproval for Manufacturing and Marketing of Micatrio
Press Release September 28, 2016 Nippon Boehringer Ingelheim Co., Ltd. Astellas Pharma Inc. Approval for Manufacturing and Marketing of Micatrio Combination Tablets, an Antihypertensive Drug Japan s first
More informationANCHOR Study Results Overview
TM ANCHOR Study Results Overview April 18, 2010 Nasdaq: AMRN www.amarincorp.com 1 Forward Looking Statement This presentation contains forward looking statements, including those relating to the Company
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Diovan, Diovan HCT, Exforge, Exforge HCT, Teveten) Reference Number: CP.HNMC.16 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Olmesartan/Amlodipine (Azor), Olmesartan/Amlodipine/ HCTZ (Tribenzor) Reference Number: CP.CPA.XX Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial See Important
More informationPhysician/Clinic Collaborative Practice Agreement
Physician/Clinic Collaborative Practice Agreement Effective October 1, 2010, Connecticut Senate Bill 428 (PA 10-117) extends to all settings and medical conditions the opportunity for licensed pharmacists
More informationREFERENCE CODE GDHC220DFR PUBLICAT ION DATE JULY 2013 JANUVIA (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC220DFR PUBLICAT ION DATE JULY 2013 JANUVIA (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Januvia for Type 2 diabetes in the 10 major pharmaceutical markets
More informationMedications for Type 2 Diabetes CDE Exam Preparation. Wendy Graham, RD, CDE Mentor, WWD Angela Puim, RPh, CDE, CRE Preston Medical Pharmacy
Medications for Type 2 Diabetes CDE Exam Preparation Wendy Graham, RD, CDE Mentor, WWD Angela Puim, RPh, CDE, CRE Preston Medical Pharmacy Competency for CDE Exam 3.1.A Oral Medications for Type 2 Diabetes
More informationPhase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018
Phase 3 investigation of aprocitentan for resistant hypertension management Investor Webcast June 2018 The following information contains certain forward-looking statements, relating to the company s business,
More informationAngiotensin II Receptor Blockers Dosage in hypertensive patients as well as patients with left ventricular hypertrophy
Angiotensin II Receptor Blockers [Developed, August 1996; Revised, December 1996; July 1997; June 1998; July 1999; September 2000; July 2001; September 2001; July 2002; July 2003; April 2008; March 2011;
More informationREFERENCE CODE GDHC45PIDR PUBLICATION DATE JUNE 2013
REFERENCE CODE GDHC45PIDR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE Executive Summary CHF: Key Metrics in the Seven Major Pharmaceutical Markets* 2012 Epidemiology CHF prevalent population 2012
More informationGalvus the most comprehensively studied DPP-4 inhibitor
Galvus the most comprehensively studied DPP-4 inhibitor! >7 000 patients enrolled in clinical studies! >4 00 patients exposed to Galvus >1 300 patients exposed 2 weeks >300 patients exposed for 104 weeks!
More informationSlide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes
Slide 1 Lars Fruergaard Jørgensen President and CEO ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationHERBAL APPROACHES TO HYPERLIPIDEMIA. Patrick M. Fratellone, MD, RH (AHG), FIM, FACC New York, New York
HERBAL APPROACHES TO HYPERLIPIDEMIA Patrick M. Fratellone, MD, RH (AHG), FIM, FACC New York, New York Patrick M. Fratellone, MD, RH (AHG) FIM, FACC November, 2013 CASE PRESENTATIONS CASE #1 46 YEAR OLD
More informationAmlodipine/Valsartan (Exforge ) Changing the Landscape of BP Management
Amlodipine/Valsartan (Exforge ) Changing the Landscape of BP Management Bum-Kee Hong Yongdong Severance Hospital Yonsei University College of Medicine Rationale for Multiple-Mechanism Therapy Inadequacy
More informationMedications for Type 2 Diabetes CDE Exam Preparation
Medications for Type 2 Diabetes CDE Exam Preparation Medications for Type 2 Diabetes CDE Exam Preparation Wendy Graham, RD, CDE Mentor, WWD Angela Puim, RPh, CDE, CRE Preston Medical Pharmacy Agenda Medication
More informationSTEP THERAPY ALGORITHMS PUP Select Formulary
The Step Therapy drug will be dispensed if the drug has been dispensed within 120 days of current fill or if alternative (Step 1) drugs have been used first. If the member s prescription claim fails the
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationEli Lilly and Company Investment Community Meeting
Eli Lilly and Company Investment Community Meeting October 3, 2013 8:30 a.m. 12:30 p.m. Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current
More informationREFERENCE CODE GDHC233DFR PUBLICAT ION DATE JULY 2013 ALBIGLUTIDE (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC233DFR PUBLICAT ION DATE JULY 2013 ALBIGLUTIDE (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Albiglutide for Type 2 diabetes in the 10 major pharmaceutical
More informationDon t let the pressure get to you:
Balanced information for better care Don t let the pressure get to you: Current evidence-based goals for treating hypertension A cornerstone of primary care: Lowering high blood pressure prevents cardiovascular
More informationUS pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
More informationA proprietary natural product that is a candidate for drug development as a monotherapy and in combination with statins
A proprietary natural product that is a candidate for drug development as a monotherapy and in combination with statins HEP-40 Mechanism & Manufacturing Mechanism Manufacturing & Purification HEP-40 binds
More information9/13/2017. Presented by UIC College of Nursing Jessy Thomas FNP, MSN, MPH. Introduction Background Management
Presented by UIC College of Nursing Jessy Thomas FNP, MSN, MPH Introduction Background Management 2 1. Provide a basic level of knowledge regarding hypertension and hyperlipidemia to care coordinators/
More informationMedicare Shared Savings Program Accountable Care Organization (ACO) Measures Deep Dive Series
Medicare Shared Savings Program Accountable Care Organization (ACO) Measures Deep Dive Series At Risk Population: Measure 33 Coronary Artery Disease (CAD-7): Angiotensin-Converting Enzyme (ACE) Inhibitor
More informationHypertension, Hyperlipidemia and Obesity. Mi-CCSI
Hypertension, Hyperlipidemia and Obesity Mi-CCSI Objectives Review the prevalence of hypertension, hyperlipidemia and obesity Correlation of the 3 conditions Discuss why it is important to treat these
More informationREFERENCE CODE GDHC238DFR PUBLICAT ION DATE JULY 2013 EMPAGLIFLOZIN (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC238DFR PUBLICAT ION DATE JULY 2013 EMPAGLIFLOZIN (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Empagliflozin for Type 2 diabetes in the 10 major pharmaceutical
More informationPre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.
Pre- Drug Use % of Treated Patients on Medication 60 50 40 30 20 10 0 1978 Diuretics ß-Blockers ACE Inhibitors Year CCBs CCBs Beta Blockers Diuretics ACE Inhibitors 1980 1982 1984 1986 1988 1990 1992 IMS
More informationREFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG Executive Summary Sales for Chronic Heart Failure in the Japan The Japan Chronic heart failure (CHF) therapeutics
More informationInvestor Presentation December The vision to see past tomorrow
Investor Presentation December 2011 The vision to see past tomorrow Safe Harbor Statement Certain statements contained herein are forward-looking statements (as such term is defined in the Private Securities
More informationUF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008
UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008 Promoting high quality, cost effective drug therapy throughout the Military Health System UF Decisions, May 07 Class FY05 rank, total $
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationGenerics. Lead with. P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m
Lead with Generics P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m WWW.BCBSLA.COM 04HQ3972 5/09 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationDon t let the pressure get to you:
Balanced information for better care Don t let the pressure get to you: An update on the changing recommendations for treating hypertension New trial data and guidelines have made hypertension care more
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationResults of Phase III Studies of Sitagliptin, new oral treatment of diabetes, were presented by Merck & Co., Inc. at ADA (The 2 nd Announcement)
June 14, 2006 Ono Pharmaceutical Co., Ltd., Public Relations Tel: +81-6-6263-5670 Banyu Pharmaceutical Co., Ltd., Public Relations Tel: +81-3-6272-1001 Results of Phase III Studies of Sitagliptin, new
More informationCardiac Medications At A Glance
Cardiac Medications At A Glance 1) Anticoagulants (Also known as Blood Thinners.) Dalteparin (Fragmin), Danaparoid (Orgaran) Enoxaparin (Lovenox) Heparin (various) Tinzaparin (Innohep) Warfarin (Coumadin)
More informationSlide 1. Investor Presentaton Jefferies Global Healthcare Conference. New York, 7 June Shanghai part of Cities Changing Diabetes
Slide 1 Investor Presentaton Jefferies Global Healthcare Conference New York, 7 June 2016 Shanghai part of Cities Changing Diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationLauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST
Lauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST Forward Looking Statements Certain statements contained
More informationPharmacy Medical Policy Angiotensin II Receptor Antagonists
Pharmacy Medical Policy Angiotensin II Receptor Antagonists Table of Contents Policy: Commercial Information Pertaining to All Policies Endnotes Policy: Medicare References Forms Policy History Policy
More informationREFERENCE CODE GDHC241DFR PUBLICAT ION DATE JULY 2013 FASIGLIFAM (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC241DFR PUBLICAT ION DATE JULY 2013 Executive Summary Fasiglifam (TAK-875): Key Metrics in the 10 Major Pharmaceutical Markets* 2022 Market Sales US $508m 5EU $127m Japan $30m China $341m
More informationEli Lilly and Company
Eli Lilly and Company Strategic Diabetes Alliance with Boehringer Ingelheim January 11 th, 2011 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More informationAdapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017
Insert Logo or Org Name Here Primary Care Medical Directive for Hypertension Management Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017 Title:
More informationPatient persistence with antihypertensive drugs in France, Germany and the UK
Patient persistence with antihypertensive drugs in France, Germany and the UK B. Ehlken (1), K. Kostev (1), A. Sandberg (2), B. Holz (1), A. M. S. Oberdiek (2) (1) IMS Health Frankfurt / Munich, Germany
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationCardioPharma. CP-101 CardiaPill The Game Changer in Treating CVD
1 CardioPharma CP-101 CardiaPill The Game Changer in Treating CVD 2 Forward looking statements This presentation includes forward-looking statements including statements regarding the timing and outcome
More informationAzilsartan Medoxomil (Edarbi) The Eighth Angiotensin II Receptor Blocker
Medoxomil (Edarbi) The Eighth Angiotensin II Receptor Blocker Jocelyn D. Jones, PharmD, BCPS; Sylvia H. Jackson, PharmD, MEd, CDE; Carmen Agboton, PharmD; and Tonya S. Martin, PharmD, CGP, MAEd INTRODUCTION
More informationDaiichi Sankyo s U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In
Daiichi Sankyo s U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In Tokyo, Japan and Basking Ridge, NJ June 6, 2018 Daiichi
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationVolume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011)
Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011) What s new in hypertension? NICE has issued an updated Clinical
More informationREFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013
REFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013 Executive Summary Diovan (valsartan): Key Metrics in the Seven Major Pharmaceutical Markets* 2012 Market Sales US - Diovan 5EU - Diovan Japan - Diovan
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationChronic hypertension is a major risk factor for cardiovascular
At a Glance Practical Implications e80 Author Information e85 Full text and PDF Single-Pill Versus Loose-Dose Combination Triple Therapy for Hypertension: Formulary Impact Original Research Kristine Ogden,
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationII. Angiotensin Receptor Blockers (ARBs) Drug Class Review
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE DOD BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32 C.F.R. 199.21,
More informationMi-CCSI welcomes you to the 2 nd in our 4 part Basics of Disease Management Webinar Series
Our speaker today is: Susan Vos, BSN, RN, CCM Mi-CCSI welcomes you to the 2 nd in our 4 part Basics of Disease Management Webinar Series We will be starting shortly A few housekeeping items: We will be
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationMerrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004
Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationACP Brief Fall 2006 prioritization. Angiotensin II Receptor Blockers (ARBs) for Proteinuria, Hypertension (HTN) and Congestive Heart Failure (CHF)
ACP Brief Fall 2006 prioritization Angiotensin II Receptor Blockers (ARBs) for Proteinuria, Hypertension (HTN) and Congestive Heart Failure (CHF) Background This topic was submitted by BC PharmaCare during
More informationAdult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More information4/3/2014 OBJECTIVES BLOOD PRESSURE BASICS. Discuss the new blood pressure guidelines (JNC 8) and recognize the changes from JNC 7
1 OBJECTIVES Discuss the new blood pressure guidelines (JNC 8) and recognize the changes from JNC 7 Review mechanisms for the main drug classes used to treat hypertension Describe the dosing strategies
More informationStudy 1 ( ) Pivotal Phase 3 Long-Term Safety Study Top-Line Results
Study 1 (1002-040) Pivotal Phase 3 Long-Term Safety Study Top-Line Results May 2, 2018 1 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE Safe Harbor Forward-Looking Statements These
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationResults of Phase II Studies of Sitagliptin (MK-0431 / ONO-5345) Investigational Treatment for Type 2 Diabetes Presented by Merck & Co., Inc.
Ono Pharmaceutical Co., Ltd., Public Relations Tel: +81-6-6263-5670 June 13, 2005 Banyu Pharmaceutical Co., Ltd., Public Relations Tel: +81-3-5203-8105 Results of Phase II Studies of Sitagliptin (MK-0431
More informationDeutsche Securities Inc. Japan Pharmaceutical Conference September 29th, 2008
Deutsche Securities Inc. Japan Pharmaceutical Conference 2008 September 29th, 2008 Takeshi Ogita Executive Officer, General Manager, Global Project Management Dept. Daiichi Sankyo R&D Pipeline Phase 1
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 RASILEZ HCT 150 mg/12.5 mg, film-coated tablets B/30 (CIP code: 392 151-6) RASILEZ HCT 150 mg/25 mg, film-coated
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationExplore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management
Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management Jeong Bae Park, MD,PhD Dept of Med/Cardiology, Cheil General Hospital, Kwandong University College of Medicine Apr
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More information4Q and Full Year 2017 Financial Results Call February 7, 2018
4Q and Full Year 2017 Financial Results Call February 7, 2018 Agenda Topic Welcome Opening Remarks 4Q 2017 Results Commercial Progress Question & Answer Speakers Amy Sullivan, SVP, Corporate Affairs Greg
More informationDry Eye Syndrome - Current and Future Players. GDHC1016FPR / Published May 2013
Dry Eye Syndrome - Current and Future Players GDHC1016FPR / Published May 2013 Executive Summary Significant growth is expected in the DES market from 2012-2022. GlobalData estimates 2012 DES therapeutic
More informationDeaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals
Takeaways: Diabetes Drug Investigation From: BSardi@aol.com Sent: Mon, Dec 22, 2014 at 10:51 am To: Cc: gemcap2@reagan.com martie.whittekin@verizon.net, katjames008@gmail.com clip_image002.jpg (64.5 KB)
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationDaiichi Sankyo s Once-Daily Lixiana
Daiichi Sankyo s Once-Daily Lixiana (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationDiabetes Complications Guideline Based Screening, Management, and Referral
Diabetes Complications Guideline Based Screening, Management, and Referral Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine Assistant Medical Director Altru Diabetes
More informationMerrill Lynch Global Healthcare Conference February 4, Shire Pharmaceuticals Group plc
Merrill Lynch Global Healthcare Conference February 4, 2003 Shire Pharmaceuticals Group plc Comment on the Safe Harbor Statement under the Private Securities Litigation Reform Act of 995 The statements
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationBrent M. Egan, MD Professor of Medicine USCSOM Greenville
Contemporary Management of Uncontrolled and Treatment Resistant Hypertension Brent M. Egan, MD Professor of Medicine USCSOM Greenville Disclosures (past 3 years): Honoraria: BCBSSC, Medtronic Grant Support:
More informationAn Update from Daiichi Sankyo
JP Morgan Healthcare Conference 2014 An Update from Daiichi Sankyo January 13, 2014 San Francisco, CA, USA George Nakayama, President and CEO About Daiichi Sankyo One of the Top pharmaceutical companies
More informationANGIOTENSIN RECEPTOR BLOCKERS
Step Therapy 2014 2 Tier-Alameda Last Updated: 10/10/2014 ANGIOTENSIN RECEPTOR BLOCKERS Benicar Benicar Hct Diovan Valsartan Step 1: First line therapy should be irbesartan, irbesartan/hctz, losartan,
More informationIndividual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki
Individual management of arterial hypertension Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki From Population to Individual Management of Arterial Hypertension Epidemiologic impact
More informationDiabetes and the Elderly: Medication Considerations When Determining Benefits and Risks
Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks Gretchen M. Ray, PharmD, PhC, BCACP, CDE Associate Professor UNM College of Pharmacy September 7 th, 2018 DISCLOSURES
More informationMerrill Lynch Healthcare Conference New York
Merrill Lynch Healthcare Conference New York Matthew Emmens Chief Executive Officer February 3, 2004 A Strategic Review Today and Beyond Clear Strengths Highly successful business model Strong pipeline
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Shire plc January 10, 2012 Angus Russell Chief Executive Officer Our purpose We enable people with life-altering conditions to lead better lives. THE SAFE HARBOR STATEMENT
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More information